Signaturefd LLC Has $434,000 Holdings in Genmab A/S (NASDAQ:GMAB)

Signaturefd LLC lifted its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 163.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 20,790 shares of the company's stock after buying an additional 12,890 shares during the quarter. Signaturefd LLC's holdings in Genmab A/S were worth $434,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC raised its position in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after buying an additional 950 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the period. Cromwell Holdings LLC lifted its position in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after acquiring an additional 2,496 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of Genmab A/S during the 4th quarter worth $93,000. Institutional investors own 7.07% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Truist Financial dropped their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Finally, BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.33.

Remove Ads

Genmab A/S Stock Down 1.2 %

NASDAQ GMAB traded down $0.23 on Tuesday, hitting $19.06. The company's stock had a trading volume of 1,209,212 shares, compared to its average volume of 917,997. The company's 50-day moving average is $21.00 and its 200 day moving average is $22.06. The firm has a market cap of $12.61 billion, a PE ratio of 10.95, a PEG ratio of 2.65 and a beta of 0.98. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.02.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts expect that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.